Key facts
- This page summarizes Andrew Spaventa's Form 4 filing for Singular Genomics Systems, Inc..
- 5 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 14 Feb 2025, 17:00.
Andrew Spaventa - 12 Feb 2025 Form 4 Insider Report for Singular Genomics Systems, Inc.
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- N/A
- Reported as of
- 12 Feb 2025
- Net transaction value
- -$15,912
- SEC form
- 4
- Accepted by SEC
- 14 Feb 2025, 17:00:10 UTC
- Prior SEC filing
- 17 Dec 2024
- Next SEC filing
- 25 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Dalen Meeter, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Andrew Spaventa filed Form 4 for Singular Genomics Systems, Inc. on 14 Feb 2025.
Change
- Previous filing in this sequence was filed on 17 Dec 2024.
- Current net transaction value: -$15,912.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
OMIC
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +1,907
- Change %
- +587%
- Price
- Shares after
- 2,232
- Date
- 12 Feb 2025
- Ownership
- Direct
- Footnotes
- F1
OMIC
transaction
Common Stock
Sale
- Transaction value
- $15,912
- Shares
- -800
- Change %
- -36%
- Price
- $19.89
- Shares after
- 1,432
- Date
- 14 Feb 2025
- Ownership
- Direct
- Footnotes
- F2, F3
OMIC
transaction
Common Stock
Gift
- Transaction value
- $0
- Shares
- -1,107
- Change %
- -77%
- Price
- $0.000000
- Shares after
- 325
- Date
- 14 Feb 2025
- Ownership
- Direct
- Footnotes
- F4
OMIC
transaction
Common Stock
Gift
- Transaction value
- $0
- Shares
- +1,107
- Change %
- +0.78%
- Price
- $0.000000
- Shares after
- 142,900
- Date
- 14 Feb 2025
- Ownership
- By The Andrew K. Spaventa Living Trust dated April 9, 2014
- Footnotes
- F4
OMIC
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 85
- Date
- 12 Feb 2025
- Ownership
- By Axon Holdings, LLC
- Footnotes
- F5
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
OMIC
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -1,907
- Change %
- -7.7%
- Price
- $0.000000
- Shares after
- 22,873
- Date
- 12 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,907
- Exercise price
- Footnotes
- F6, F7
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 7 footnotes
Footnote F1
Represents shares of Common Stock issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
Footnote F2
The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted RSUs.
Footnote F3
Represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $19.88 to $19.91, inclusive. For all transactions reported in this Form 4 utilizing a weighted-average price, the reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Footnote F4
Immediately upon settlement of the vested RSUs, and following the withholding described above, the Reporting Person transferred the shares as a gift to The Andrew K. Spaventa Living Trust dated April 9, 2014.
Footnote F5
The shares are held directly by Axon Holdings, LLC. The managing member of Axon Holdings, LLC is Axon Managers, LLC. The Reporting Person is a managing member of Axon Managers, LLC and may be deemed to have shared voting and investment power over the shares held by Axon Holdings, LLC. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
Footnote F6
Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
Footnote F7
The RSUs vest in 16 equal quarterly installments over four years measured from February 12, 2024.